Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    November 2022
  1. MORRILL JC, Peters CJ, Bettinger GE, Palermo PM, et al
    Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01339.
    PubMed     Abstract available


    October 2022
  2. RABE APJ, Costello P, Were JJ, Farrer A, et al
    The burden of selected vaccine-preventable diseases on the secondary care health system in England: Results from a five-year administrative healthcare dataset.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01263.
    PubMed     Abstract available


    September 2022
  3. KUIPER VP, van der Plas P, Hoogerwerf MA, Pieter R Koopman J, et al
    A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01100.
    PubMed     Abstract available


  4. FENG T, Li M, Zhang L, Li S, et al
    Immunity of two novel hepatitis C virus polyepitope vaccines.
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01115.
    PubMed     Abstract available


    August 2022
  5. ROMANO L, Tosti ME, Zanetti AR
    Beyond 30 years of universal anti-hepatitis B vaccination in Italy: Success and areas of improvement.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00966.
    PubMed    


    July 2022
  6. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    PubMed     Abstract available


    May 2022
  7. OSTER G, Bornheimer R, Ottino K, Stevenson C, et al
    Adult immunization against hepatitis B: Does the number of jabs matter?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00534.
    PubMed     Abstract available


    April 2022
  8. BEULENS C, Raven SFH, van Jaarsveld CHM, van Loo I, et al
    Evaluation of a personalized, dose-sparing revaccination strategy in hepatitis B vaccine non-responders.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00470.
    PubMed     Abstract available


    March 2022
  9. BURNY W, Herve C, Caubet M, Yarzabal JP, et al
    Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00361.
    PubMed     Abstract available


  10. BREAKWELL L, Marke D, Kaiser R, Tejada-Strop A, et al
    Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00360.
    PubMed     Abstract available


    February 2022
  11. DE LUCA C, Schachner A, Heidl S, Hess M, et al
    Vaccination with a fowl adenovirus chimeric fiber protein (crecFib-4/11) simultaneously protects chickens against hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH).
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00116.
    PubMed     Abstract available


    January 2022
  12. PITTET LF, Cox L, Freyne B, Germano S, et al
    Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner.
    Vaccine. 2022 Jan 29. pii: S0264-410X(22)00020.
    PubMed     Abstract available


    November 2021
  13. URUENA A, Badano MN, Bare P, Gonzalez J, et al
    Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis A in Argentinian children.
    Vaccine. 2021 Nov 24. pii: S0264-410X(21)01482.
    PubMed     Abstract available


  14. GORDEYCHUK I, Kyuregyan K, Kondrashova A, Bayurova E, et al
    Immunization with recombinant ORF2 p551 protein protects common marmosets (Callithrix jacchus) against homologous and heterologous hepatitis E virus challenge.
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01487.
    PubMed     Abstract available


  15. HAFNER-GIESSAUF H, Horn S, Schwantzer G, Sprenger-Mahr H, et al
    Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01474.
    PubMed     Abstract available


  16. THULUVA S, Matur R, Tsa K, Gv SR, et al
    A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV(TM)) in 1-15 years-old healthy hepatitis A vaccine-naive children.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01326.
    PubMed     Abstract available


    October 2021
  17. NETANEL C, Ben-Aharon O, Ben-Ari Z, Chodick G, et al
    Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016.
    Vaccine. 2021 Oct 20. pii: S0264-410X(21)01287.
    PubMed     Abstract available


  18. DANKWA EA, Donnelly CA, Brouwer AF, Zhao R, et al
    Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United states.
    Vaccine. 2021 Oct 19. pii: S0264-410X(21)01308.
    PubMed     Abstract available


  19. SRICHAN P, Thohinung U, Kodyee S, Apidechkul T, et al
    Vaccine serocoverage under the expanded program on immunization among hill tribe children in Thailand: A cross-sectional study.
    Vaccine. 2021 Oct 1. pii: S0264-410X(21)01264.
    PubMed     Abstract available


    September 2021
  20. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    PubMed     Abstract available


  21. HOFMEISTER MG, Weng MK, Thoroughman D, Thomasson ED, et al
    Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016-2019.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01254.
    PubMed     Abstract available


  22. CHOWDHURY F, Akter A, Rahman Bhuiyan T, Tauheed I, et al
    A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01222.
    PubMed     Abstract available


  23. ELBASHA EH, Choi Y, Daniels V, Goveia MG, et al
    Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01147.
    PubMed     Abstract available


    August 2021
  24. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    PubMed     Abstract available


  25. WANG R, Chen K, Wang Y, Liu C, et al
    Booster immunization improves the generation of T follicular helper (Tfh) cells specific to hepatitis B surface antigen (HBsAg) after prenatal HBsAg exposure.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01040.
    PubMed     Abstract available


  26. JANSSEN RS, Bruxvoort K, Jacobsen SJ, Slezak J, et al
    Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01015.
    PubMed     Abstract available


  27. GALOR I, Hartal M, Perry Markovich M, Avramovich E, et al
    Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule: Response letter, to letter to the editor.
    Vaccine. 2021;39:4777.
    PubMed    


  28. HERZOG C
    Immune memory persistence is well documented for hepatitis A vaccines.
    Vaccine. 2021;39:4775-4776.
    PubMed    


    July 2021
  29. DOI H, Kanto T
    Factors influencing the durability of hepatitis B vaccine responses.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00876.
    PubMed     Abstract available


  30. GOSSET A, Diallo MY, Betsem E, Schaeffer L, et al
    Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NeoVac Study).
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00809.
    PubMed     Abstract available


    June 2021
  31. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    PubMed     Abstract available


  32. DIAZ-MITOMA F, Popovic V, Spaans JN
    Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac(R), compared with Engerix-B(R) in healthy Asian adults: A phase 3 randomized clinical trial.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00662.
    PubMed     Abstract available


  33. YANG T, Liu B, Yue L, Xie T, et al
    Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00653.
    PubMed     Abstract available


    May 2021
  34. HIRST A, Hyer RN, Janssen RS
    Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00582.
    PubMed     Abstract available


  35. AWAD AM, Ntoso A, Connaire JJ, Hernandez GT, et al
    An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B(R)) in adults receiving hemodialysis.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00554.
    PubMed     Abstract available


  36. HAN B, Liu W, Du J, Liu H, et al
    Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00540.
    PubMed     Abstract available


  37. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    PubMed     Abstract available


  38. TAMANDJOU TCHUEM CR, Andersson MI, Wiysonge CS, Mufenda J, et al
    Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00498.
    PubMed     Abstract available


    April 2021
  39. MARTIN JC, Petrecz ML, Stek JE, Simon JK, et al
    Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA).
    Vaccine. 2021 Apr 15. pii: S0264-410X(21)00345.
    PubMed     Abstract available


  40. YAO T, Shao Z, Wu L, Dong S, et al
    Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China.
    Vaccine. 2021 Apr 2. pii: S0264-410X(21)00378.
    PubMed     Abstract available


    March 2021
  41. EL BARA A, Pivert A, Veillon P, Ng Wing Sang C, et al
    From national HBV and HDV screenings to vaccination and treatment in healthcare workers: The Mauritanian pilot study.
    Vaccine. 2021 Mar 19. pii: S0264-410X(21)00279.
    PubMed     Abstract available


    November 2020
  42. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31387.
    PubMed     Abstract available


    September 2020
  43. ISTRATE A, Azoicai D, Almas A, Radulescu A, et al
    Variable anti-HBs antibody titers in vaccinated birth cohorts - A cross-sectional population-based study.
    Vaccine. 2020 Sep 19. pii: S0264-410X(20)31184.
    PubMed     Abstract available


    July 2020
  44. CELZO F, Buyse H, Welby S, Ibrahimi A, et al
    Safety evaluation of adverse events following vaccination with Havrix, Engerix-B or Twinrix during pregnancy.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30970.
    PubMed     Abstract available


    June 2020
  45. YU W, Cao L, Liu Y, Li K, et al
    Two media-reported vaccine events in China from 2013 to 2016: Impact on confidence and vaccine utilization.
    Vaccine. 2020 Jun 30. pii: S0264-410X(20)30632.
    PubMed     Abstract available


    February 2020
  46. ZAHN T, Akhras S, Spengler C, Murra RO, et al
    A new approach for therapeutic vaccination against chronic HBV infections.
    Vaccine. 2020 Feb 26. pii: S0264-410X(20)30291.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: